Research Studies

Pelton and Fellrose Medical Group works regularly with our colleagues across the NHS and beyond to try and help our patients. Please see below details of research studies the practice is currently participating in.


We would like to invite you to take part in the SOLID study, which aims to identify people with liver disease before irreversible damage has occurred. Undiagnosed liver disease is common in the community and it is often not identified as people have no symptoms.

If patients agree to take part, this can be done as part of your annual review with the surgery. Please be aware appointments for this will not be available on a Friday.

Please read the Patient Information Sheet below and if you are interested please check your eligibility via the link below.

To check eligibility and provide e-consent:

Electronic Risk Assessment for Cancer (ERICA)

The study will aim to find out whether electronic Risk Assessment Tools (eRATs) help GPs diagnose more cancers at an earlier stage compared to usual care for patients in general practice and if they are financially economical for the NHS.

Maximising Adherence & Gaining New Information for Your COPD (MAGNIFY)

To evaluate the impact of an enhanced adherence package (dual bronchodilator inhaler + adherence technology device with mobile app) on time to treatment failure and other clinical outcomes in exacerbating COPD patients with poor adherence to mono or dual therapy over one year.

Newcastle NIHR BioResource

Establishing a database of healthy individuals with neurological, cardiovascular, or infectious/inflammatory or immune disorders or rare diseases who are consented for recall for research on the basis of genotype or phenotype. The aim is to build on and integrate existing resources to promote recruitment of well genotyped and phentoyped participants into local and national studies coordinated through existing clinics within NIHR Biomedical Research Units and Centres.

Care 75+

To establish a cohort of older people with frailty for observational research and as facility for future clinical trials of interventions. This is an innovative cohort method Randomised Control Trial (cmRCT) approach.

Active Brain

A new website called ‘Active Brains’ aims to help older adults to look after their brain and body health to prevent cognitive decline. The website supports older adults to make simple behavioural changes such as increasing physical activity, playing brain training games and finding ways to eat more healthy. This study will trial the effectiveness and cost effectiveness of ‘Active Brains’. The trial will recruit two groups of older adults: 1) those with signs of cognitive decline, 2) those without any cognitive decline. Members of both of these groups will be randomly assigned to one of three trial groups: 1) care as they usually receive it from their GP practice, or 2) access to the Active Brains website, or 3) access to the Active Brains website plus brief support from a trained person (over the phone or by email). The trial will last for five years.

Aspirin to target Arterial Events in Chronic Kidney Disease (ATTACK)

ATTACK is an open-label multicentre randomised controlled study to test the
hypothesis that the addition of 75mg aspirin once daily to usual care (no aspirin)
reduces the risk of major vascular events in patients with chronic kidney disease
(CKD) who do not have pre-existing cardiovascular disease (CVD).
The study will recruit adults with CKD and no previous CVD via their GP practice.
Eligible patients will be allocated to receive low-dose aspirin (75mg non-enteric
coated) or not. Patients will be followed up for several years
(electronically/questionnaires) to determine whether aspirin should be prescribed to
this population in the future.


Intervention with cancer diagnosis and follow up.